Condition: Non Small Cell Lung Cancer · Non Small Cell Lung Cancer Metastatic · Non-small Cell Carcinoma · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
This description comes directly from the study's public registry record.
Paul Romesser, MD · 646-888-2118 · romessep@mskcc.org
Daniel Gomez, MD · 212-639-2087 · gomezd@mskcc.org
Always discuss trial participation with your own doctor first.
| BAPTIST ALLIANCE - MCI (Data Collection Only) | Miami, Florida, United States | Recruiting |
| Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (All protocol activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (All protocol activities) | Rockville Centre, New York, United States | Recruiting |
| Lehigh Valley Health Network (Data Collection Only) | Allentown, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05657873